For hypertension or with congestive heart failure. ANDA 71111, held by Barr Laboratories. Amiloride Hydrochloride; Hydrochlorothiazide.
As of Nov 22, 2026, ANDA 71111 (Amiloride Hydrochloride and Hydrochlorothiazide), held by Barr Laboratories, was first approved by FDA on May 10, 1988, with 21 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 10, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amiloride Hydrochloride and HydrochlorothiazideEQ 5MG ANHYDROUS;50MG · tablet;oral | Amiloride Hydrochloride; Hydrochlorothiazide | Rx |
| Aug 20, 2020 | Supplement 34Labeling · Standard review | Approved | None posted |
| Sep 18, 2002 | Supplement 25Labeling | Approved | None posted |
| Jul 15, 2002 | Supplement 24Labeling | Approved | None posted |
| Oct 16, 2000 | Supplement 21Manufacturing | Approved | None posted |
| Oct 16, 2000 | Supplement 22Manufacturing | Approved | None posted |
| Dec 21, 1999 | Supplement 23Manufacturing | Approved | None posted |
| May 20, 1999 | Supplement 20Manufacturing | Approved | None posted |
| Dec 1, 1998 | Supplement 19Manufacturing | Approved | None posted |
| Jul 1, 1998 | Supplement 18Manufacturing | Approved | None posted |
| Jul 25, 1997 | Supplement 17Manufacturing | Approved | None posted |
| Dec 23, 1994 | Supplement 16Manufacturing | Approved | None posted |
| Oct 11, 1994 | Supplement 15Manufacturing | Approved | None posted |
| Apr 14, 1993 | Supplement 14Labeling | Approved | None posted |
| Apr 3, 1992 | Supplement 11Manufacturing | Approved | None posted |
| Apr 3, 1992 | Supplement 13Manufacturing | Approved | None posted |
| Dec 16, 1991 | Supplement 10Labeling | Approved | None posted |
| Mar 26, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Mar 26, 1991 | Supplement 7Manufacturing | Approved | None posted |
| Mar 26, 1991 | Supplement 8Manufacturing | Approved | None posted |
| Mar 26, 1991 | Supplement 9Manufacturing | Approved | None posted |
| Dec 6, 1989 | Supplement 5Manufacturing | Approved | None posted |
| May 10, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters